SI2493895T1 - Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze - Google Patents

Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze

Info

Publication number: SI2493895T1
Authority: SI; Slovenia
Prior art keywords: kinase inhibitors; containing heteroaryl; jak3 kinase; heteroaryl derivatives; derivatives
Prior art date: 2009-10-29

Application number

SI201031506T

Other languages

English (en)

Inventor

Rosales Carmen Almansa

Solana Jorge Salas

Soliva Robert Soliva

Escrich Sergio Rodriguez

Gonzalez Maria Cristina Sicre

Original Assignee

Vectura Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-29

Filing date

2010-10-29

Publication date

2017-10-30

2010-10-29 Application filed by Vectura Limited filed Critical Vectura Limited

2017-10-30 Publication of SI2493895T1 publication Critical patent/SI2493895T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Obesity (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SI201031506T 2009-10-29 2010-10-29 Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze SI2493895T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP09382233		2009-10-29
US29105109P	2009-12-30	2009-12-30
US32992710P	2010-04-30	2010-04-30
EP10771146.7A EP2493895B1 (en)	2009-10-29	2010-10-29	N-containing heteroaryl derivatives as jak3 kinase inhibitors
PCT/EP2010/066476 WO2011051452A1 (en)	2009-10-29	2010-10-29	N-containing heteroaryl derivatives as jak3 kinase inhibitors

Publications (1)

Publication Number	Publication Date
SI2493895T1 true SI2493895T1 (sl)	2017-10-30

Family

ID=41571618

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201031506T SI2493895T1 (sl)	2009-10-29	2010-10-29	Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze

Country Status (23)

Country	Link
US (2)	US8501735B2 (sl)
EP (1)	EP2493895B1 (sl)
JP (1)	JP5759471B2 (sl)
KR (1)	KR101675614B1 (sl)
CN (1)	CN102712658B (sl)
AR (1)	AR078833A1 (sl)
AU (1)	AU2010311378B2 (sl)
BR (1)	BR112012010186B8 (sl)
CA (1)	CA2778680C (sl)
DK (1)	DK2493895T3 (sl)
ES (1)	ES2629006T3 (sl)
HK (1)	HK1172327A1 (sl)
IL (1)	IL219385A0 (sl)
MX (1)	MX2012005100A (sl)
PE (1)	PE20121352A1 (sl)
PL (1)	PL2493895T3 (sl)
PT (1)	PT2493895T (sl)
RU (1)	RU2553681C2 (sl)
SI (1)	SI2493895T1 (sl)
TW (1)	TWI478714B (sl)
UA (1)	UA109775C2 (sl)
WO (1)	WO2011051452A1 (sl)
ZA (1)	ZA201203090B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2397482A1 (en) *	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
CA2803448A1 (en) *	2010-07-06	2012-01-12	Universite De Montreal	Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2012100342A1 (en)	2011-01-27	2012-08-02	Université de Montréal	Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013025628A1 (en) *	2011-08-15	2013-02-21	Ligand Pharmaceuticals Incorporated	Janus kinase inhibitor compounds and methods
AU2012340869B2 (en)	2011-11-23	2017-03-02	Cancer Research Technology Limited	Thienopyrimidine inhibitors of atypical protein kinase C
UY34615A (es) *	2012-02-10	2013-09-30	Galapagos Nv	Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
WO2013117649A1 (en) *	2012-02-10	2013-08-15	Galapagos Nv	Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
TW201513861A (zh) *	2013-01-17	2015-04-16	Galapagos Nv	用於治療退化性及發炎疾病之新穎化合物
WO2014145852A2 (en) *	2013-03-15	2014-09-18	Knopp Biosciences Llc	Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US9067914B1 (en)	2013-12-10	2015-06-30	Genzyme Corporation	Tropomyosin-related kinase (TRK) inhibitors
AU2015231215B2 (en)	2014-03-20	2019-07-18	Capella Therapeutics, Inc.	Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
HRP20231071T1 (hr)	2014-09-12	2024-03-01	Biohaven Therapeutics Ltd.	Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala
TWI696621B (zh)	2014-12-18	2020-06-21	美商健臻公司	原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
EP3053927A1 (en) *	2015-02-05	2016-08-10	Vectura Limited	Novel polymorphs
EP3268364A1 (en)	2015-03-10	2018-01-17	Vectura Limited	Crystalline form of a jak3 kinase inhibitor
US10189841B2 (en)	2015-11-20	2019-01-29	Forma Therapeutics, Inc.	Purinones as ubiquitin-specific protease 1 inhibitors
ES2946551T3 (es)	2017-10-17	2023-07-20	Palau Pharma S L U	Síntesis de compuestos de 4-aminopirimidina
TWI820146B (zh)	2018-06-15	2023-11-01	瑞典商阿斯特捷利康公司	嘌呤酮化合物及其在治療癌症中之用途
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
CN112724133B (zh) *	2021-01-12	2022-03-25	湖南复瑞生物医药技术有限责任公司	6-溴吡唑并[1,5-a]吡啶的制备方法
WO2023248010A2 (en)	2022-06-23	2023-12-28	Synovo Gmbh	Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
US20240261224A1 (en)	2022-12-02	2024-08-08	Kinaset Therapeutics, Inc.	Formulation of a pan-jak inhibitor

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
WO2004039796A1 (de)	2002-10-28	2004-05-13	Bayer Healthcare Ag	Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
EP1505064A1 (en)	2003-08-05	2005-02-09	Bayer HealthCare AG	2-Aminopyrimidine derivatives
AR050188A1 (es) *	2004-08-03	2006-10-04	Uriach Y Compania S A J	Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
CA2577947A1 (en) *	2004-08-31	2006-03-09	Banyu Pharmaceutical Co., Ltd.	Novel substituted imidazole derivative
WO2006053109A1 (en)	2004-11-10	2006-05-18	Synta Pharmaceuticals Corp.	Heteroaryl compounds
CA2604161A1 (en)	2005-04-05	2006-10-12	Pharmacopeia, Inc.	Purine and imidazopyridine derivatives for immunosuppression
US7884109B2 (en)	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
WO2006110763A1 (en)	2005-04-08	2006-10-19	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives and their use for the treatment of cancer
WO2006124874A2 (en)	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
US8580802B2 (en) *	2005-09-30	2013-11-12	Vertex Pharmaceuticals Incorporated	Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases
NL2000323C2 (nl)	2005-12-20	2007-11-20	Pfizer Ltd	Pyrimidine-derivaten.
TWI398252B (zh)	2006-05-26	2013-06-11	Novartis Ag	吡咯并嘧啶化合物及其用途
TW200831104A (en) *	2006-10-04	2008-08-01	Pharmacopeia Inc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) *	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
WO2008043019A1 (en) *	2006-10-04	2008-04-10	Pharmacopeia, Inc	8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
ES2627352T3 (es)	2006-10-19	2017-07-27	Signal Pharmaceuticals, Llc	Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
BRPI0622030A2 (pt)	2006-11-16	2014-04-22	Pharmacopeia Llc	Derivados de purina 7-substituída, para imunossupressão
US20080119496A1 (en) *	2006-11-16	2008-05-22	Pharmacopeia Drug Discovery, Inc.	7-Substituted Purine Derivatives for Immunosuppression
JP2010523522A (ja) *	2007-04-02	2010-07-15	パラウ・フアルマ・ソシエダツド・アノニマ	Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
CN101679412A (zh)	2007-05-23	2010-03-24	药典有限责任公司	作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
US8648069B2 (en) *	2007-06-08	2014-02-11	Abbvie Inc.	5-substituted indazoles as kinase inhibitors
WO2009048474A1 (en)	2007-10-12	2009-04-16	Pharmacopeia, Inc.	2,7,9-substituted purinone derivatives for immunosuppression
PE20091035A1 (es)	2007-11-30	2009-07-16	Palau Pharma Sa	Derivados de 2-aminopirimidina
AR069813A1 (es)	2007-12-19	2010-02-17	Palau Pharma Sa	Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AU2008341678B2 (en)	2007-12-21	2013-03-21	Palau Pharma, S.L.U	4 -aminopyrimidine derivatives as histamine H4 receptor antagonists
GB0815369D0 (en)	2008-08-22	2008-10-01	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
CN102803248B (zh)	2009-12-23	2015-09-16	梅迪奇制药有限公司	作为组胺h4受体拮抗剂的氨烷基嘧啶
JP2011136925A (ja) *	2009-12-28	2011-07-14	Dainippon Sumitomo Pharma Co Ltd	含窒素二環性化合物

2010
- 2010-10-29 SI SI201031506T patent/SI2493895T1/sl unknown
- 2010-10-29 CN CN201080059973.2A patent/CN102712658B/zh active Active
- 2010-10-29 RU RU2012122020/04A patent/RU2553681C2/ru active
- 2010-10-29 ES ES10771146.7T patent/ES2629006T3/es active Active
- 2010-10-29 PE PE2012000600A patent/PE20121352A1/es not_active Application Discontinuation
- 2010-10-29 AR ARP100103999A patent/AR078833A1/es active IP Right Grant
- 2010-10-29 TW TW099137263A patent/TWI478714B/zh active
- 2010-10-29 UA UAA201206551A patent/UA109775C2/ru unknown
- 2010-10-29 WO PCT/EP2010/066476 patent/WO2011051452A1/en active Application Filing
- 2010-10-29 JP JP2012535851A patent/JP5759471B2/ja active Active
- 2010-10-29 BR BR112012010186A patent/BR112012010186B8/pt active IP Right Grant
- 2010-10-29 KR KR1020127013343A patent/KR101675614B1/ko active IP Right Grant
- 2010-10-29 DK DK10771146.7T patent/DK2493895T3/en active
- 2010-10-29 CA CA2778680A patent/CA2778680C/en active Active
- 2010-10-29 AU AU2010311378A patent/AU2010311378B2/en active Active
- 2010-10-29 PT PT107711467T patent/PT2493895T/pt unknown
- 2010-10-29 EP EP10771146.7A patent/EP2493895B1/en active Active
- 2010-10-29 US US13/504,157 patent/US8501735B2/en active Active
- 2010-10-29 MX MX2012005100A patent/MX2012005100A/es active IP Right Grant
- 2010-10-29 PL PL10771146T patent/PL2493895T3/pl unknown
2012
- 2012-04-24 IL IL219385A patent/IL219385A0/en active IP Right Grant
- 2012-04-26 ZA ZA2012/03090A patent/ZA201203090B/en unknown
- 2012-12-19 HK HK12113100.6A patent/HK1172327A1/xx unknown
2013
- 2013-06-28 US US13/930,392 patent/US8946257B2/en active Active

Also Published As

Publication number	Publication date
KR101675614B1 (ko)	2016-11-11
CA2778680C (en)	2016-12-13
CN102712658A (zh)	2012-10-03
JP5759471B2 (ja)	2015-08-05
IL219385A0 (en)	2012-06-28
KR20120101402A (ko)	2012-09-13
CN102712658B (zh)	2015-06-03
RU2012122020A (ru)	2013-12-10
US8946257B2 (en)	2015-02-03
CA2778680A1 (en)	2011-05-05
PT2493895T (pt)	2017-07-05
TWI478714B (zh)	2015-04-01
AU2010311378A1 (en)	2012-05-24
BR112012010186A2 (pt)	2016-04-19
WO2011051452A1 (en)	2011-05-05
UA109775C2 (xx)	2015-10-12
TW201127385A (en)	2011-08-16
MX2012005100A (es)	2012-06-08
US20120245140A1 (en)	2012-09-27
JP2013509382A (ja)	2013-03-14
US20130131038A9 (en)	2013-05-23
US20130289015A1 (en)	2013-10-31
BR112012010186B1 (pt)	2020-11-03
EP2493895A1 (en)	2012-09-05
BR112012010186B8 (pt)	2021-05-25
ZA201203090B (en)	2013-09-25
AU2010311378B2 (en)	2014-04-24
PE20121352A1 (es)	2012-10-15
US8501735B2 (en)	2013-08-06
HK1172327A1 (en)	2013-04-19
DK2493895T3 (en)	2017-08-14
EP2493895B1 (en)	2017-04-26
PL2493895T3 (pl)	2017-10-31
RU2553681C2 (ru)	2015-06-20
AR078833A1 (es)	2011-12-07
ES2629006T3 (es)	2017-08-07

Publication	Publication Date	Title
HK1172327A1 (en)	2013-04-19	N-containing heteroaryl derivatives as jak3 kinase inhibitors jak3
HK1162022A1 (en)	2012-08-17	Picolinamide derivatives as kinase inhibitors
ZA201100344B (en)	2012-10-31	Pyrimidine derivatives as kinase inhibitors
IL218271A0 (en)	2012-04-30	Heterocyclic compounds as janus kinase inhibitors
HRP20130698T1 (en)	2013-10-11	Novel phenylpyrazinones as kinase inhibitors
IL210990A0 (en)	2011-04-28	Piperidine derivatives as jak3 inhibitors
IL213906A0 (en)	2011-07-31	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
IL208716B (en)	2018-02-28	The history of phosphorus as kinase inhibitors
HRP20130787T1 (en)	2013-09-30	Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL210292A0 (en)	2011-03-31	Heteroaryl derivatives as dgat1 inhibitors
HK1151291A1 (en)	2012-01-27	2-benzylpyridazinone derivatives as met kinase inhibitors
IL218114A0 (en)	2012-04-30	5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors
IL210573A0 (en)	2011-03-31	Compounds as kinase inhibitors
IL212842A0 (en)	2011-07-31	Azaindole derivatives as kinase inhibitors
IL220205A0 (en)	2012-07-31	Heterocyclic compounds as janus kinase inhibitors
EP2231152A4 (en)	2011-06-08	THIENOPYRANONES AS KINASE INHIBITORS
HK1156611A1 (en)	2012-06-15	Naphthyridininones as aurora kinase inhibitors aurora
EP2611806A4 (en)	2014-05-07	HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES
EP2432321A4 (en)	2014-01-01	THIAZOLOPYRIMIDINONE DERIVATIVES AS INHIBITORS OF PI3 KINASE